Your browser doesn't support javascript.
Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India.
Dhar, Mahesh S; Marwal, Robin; Vs, Radhakrishnan; Ponnusamy, Kalaiarasan; Jolly, Bani; Bhoyar, Rahul C; Sardana, Viren; Naushin, Salwa; Rophina, Mercy; Mellan, Thomas A; Mishra, Swapnil; Whittaker, Charles; Fatihi, Saman; Datta, Meena; Singh, Priyanka; Sharma, Uma; Ujjainiya, Rajat; Bhatheja, Nitin; Divakar, Mohit Kumar; Singh, Manoj K; Imran, Mohamed; Senthivel, Vigneshwar; Maurya, Ranjeet; Jha, Neha; Mehta, Priyanka; A, Vivekanand; Sharma, Pooja; Vr, Arvinden; Chaudhary, Urmila; Soni, Namita; Thukral, Lipi; Flaxman, Seth; Bhatt, Samir; Pandey, Rajesh; Dash, Debasis; Faruq, Mohammed; Lall, Hemlata; Gogia, Hema; Madan, Preeti; Kulkarni, Sanket; Chauhan, Himanshu; Sengupta, Shantanu; Kabra, Sandhya; Gupta, Ravindra K; Singh, Sujeet K; Agrawal, Anurag; Rakshit, Partha; Nandicoori, Vinay; Tallapaka, Karthik Bharadwaj; Sowpati, Divya Tej.
  • Dhar MS; National Centre for Disease Control, Delhi, India.
  • Marwal R; National Centre for Disease Control, Delhi, India.
  • Vs R; National Centre for Disease Control, Delhi, India.
  • Ponnusamy K; National Centre for Disease Control, Delhi, India.
  • Jolly B; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Bhoyar RC; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Sardana V; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Naushin S; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Rophina M; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Mellan TA; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Mishra S; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Whittaker C; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Fatihi S; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Datta M; Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK.
  • Singh P; Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK.
  • Sharma U; Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK.
  • Ujjainiya R; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Bhatheja N; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Divakar MK; National Centre for Disease Control, Delhi, India.
  • Singh MK; National Centre for Disease Control, Delhi, India.
  • Imran M; National Centre for Disease Control, Delhi, India.
  • Senthivel V; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Maurya R; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Jha N; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Mehta P; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • A V; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Sharma P; National Centre for Disease Control, Delhi, India.
  • Vr A; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Chaudhary U; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Soni N; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Thukral L; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Flaxman S; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Bhatt S; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Pandey R; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Dash D; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Faruq M; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Lall H; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Gogia H; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Madan P; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Kulkarni S; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Chauhan H; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Sengupta S; National Centre for Disease Control, Delhi, India.
  • Kabra S; National Centre for Disease Control, Delhi, India.
  • Gupta RK; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Singh SK; Department of Mathematics, Imperial College London, London, UK.
  • Agrawal A; Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK.
  • Rakshit P; Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Nandicoori V; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
  • Tallapaka KB; Academy for Scientific and Innovative Research, Ghaziabad, India.
  • Sowpati DT; CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
Science ; 374(6570): 995-999, 2021 Nov 19.
Article in English | MEDLINE | ID: covidwho-1526449
ABSTRACT
Delhi, the national capital of India, experienced multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks in 2020 and reached population seropositivity of >50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant, B.1.617.2 (Delta), replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and reduced sensitivity to immune responses generated against earlier variants (median estimates 1.5-fold greater transmissibility and 20% reduction in sensitivity). Seropositivity of an employee and family cohort increased from 42% to 87.5% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after a previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Genome, Viral / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adolescent / Adult / Child / Humans / Young adult Country/Region as subject: Asia Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abj9932

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Genome, Viral / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adolescent / Adult / Child / Humans / Young adult Country/Region as subject: Asia Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abj9932